33 / 74
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 5, September/October 2014
AFRICA
227
With the increasing use of thrombolysis on a national level, such
risk-stratification tools might be considered for inclusion into a
stroke unit protocol.
References
1.
Statistics South Africa. Mortality and causes of death in South Africa,
2007: Findings from death notification.
Statistical Release
P0309.3.
Pretoria: Statistics South Africa; 2007.
2.
Bertram MY, Katzenellenbogen J, Vos T, Bradshaw D, Hofman KJ.
The disability adjusted life years due to stroke in South Africa in 2008.
Int J Stroke
2013:1–5. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23295022.
3.
Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for
acute ischaemic stroke (Review ).
Cochrane Systematic Rev
2009;
4
.
4.
The National Institute of Neurological Disorders and Stroke rt-PA
Stroke Study Group. Tissue plasminogen activator for acute ischemic
stroke.
N Engl J Med
1995;
333
(24): 1581–1587.
5.
Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB,
Lu M,
et al.
Effects of tissue plasminogen activator for acute ischemic
stroke at one year. National Institute of Neurological Disorders and
Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
New Engl J Med
1999;
340
(23): 1781–1787. Available from: http://
content.wkhealth.com/linkback/openurl?sid
=
WKPTLP:landingpage&
an
=
00008506-199910000-00011.
6.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D,
et al.
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic
stroke.
New Engl J Med
2008;
359
(13): 1317–1329. Available from:
http://www.nejm.org/doi/full/10.1056/NEJMoa0804656.7.
Ford G, Freemantle N. ECASS-II: intravenous alteplase in acute ischae-
mic stroke.
Lancet
1999;
353
(9146): 65. Available from:
http://linking-
hub.elsevier.com/retrieve/pii/S0140673698000051.
8.
Wahlgren N, Ahmed N, Dávalos A, Ford G a, Grond M, Hacke W,
et
al.
Thrombolysis with alteplase for acute ischaemic stroke in the Safe
Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-
MOST): an observational study.
Lancet
2007;
369
(9558): 275–282.
Available from:
http://www.ncbi.nlm.nih.gov/pubmed/17258667.9.
Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clini-
cally relevant number needed to harm.
Stroke
2007;
38
(8): 2279–2283.
Available from:
http://www.ncbi.nlm.nih.gov/pubmed/17641238.10. Wasserman S, Bryer A. Early outcomes of thrombolysis for acute
ischaemic stroke in a South African tertiary care centre.
South Afr Med
J
2012;
102
(6): 541–544. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22668959.
11. Lahri S, Wallis L. South African ischaemic stroke guideline, 2010.
South
Afr Med J
2011;
101
(1): 7; author reply 7–8. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21626967.
12. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D,
et al.
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic
stroke treated with intravenous alteplase: safe implementation of treat-
ments in stroke (SITS) symptomatic intracerebral hemorrhage risk
score.
Stroke
2012;
43
(6): 1524–1531. Available from:
http://www.ncbi.
nlm.nih.gov/pubmed/22442178.
13. Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ,
et al.
Symptomatic intracranial hemorrhage after stroke thrombolysis:
The SEDAN Score.
Ann Neurol
2012;
71
(5): 634–641. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22522478.14. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D,
et
al.
Randomised double-blind placebo-controlled trial of thrombolytic
therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).
Lancet
1998;
352
(9136): 1245–1251. Available from:
http://linkinghub.elsevier.com/retrieve/pii/S0140673698080209.
Congratulations
to Michael Meadon, our content manager,
and his wife Lene, on the birth of their baby girl
Charlotte Katherine
on Friday 17 October 2014